Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 12 of 58, showing 10 Applications out of 576 total, starting on record 111, ending on 120

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

111.

ECCT/15/10/01   VRC01 Monoclonal HIV Antibodies Study
    Safety  and  Virologic Effect  Of  A  Human   Monoclonal   Antibody,   VRC-HIVmAb060-00-Ab  (VRCOl),   With Broad  HIV-1  Neutralizing Activity, Administered Intravenously to Adults  During Early Acute HIV Infection.   
Principal Investigator(s)
1. Josphat K Kosgei
Site(s) in Kenya
KEMRI Walter Reed Project Kericho
 
20-03-2016 View

112.

ECCT/16/02/01   ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘
            ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN  TURKANA COUNTY, KENYA ‘         
Principal Investigator(s)
1. ISAIAH MWANGI
Site(s) in Kenya
1. lodwar hospital (Turkana county)
 
21-03-2016 View

113.

ECCT/15/12/02   The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial
    A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD).   Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial   
Principal Investigator(s)
1. Prof Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-RCTP Study center , Lumumba
 
11-04-2016 View

114.

ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]   
Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
 
15-04-2016 View

115.

ECCT/15/08/01   Rifapentine During Intensive Phase TB Treatment
     Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial   
Principal Investigator(s)
1. Elisha Ochieng Okeyo
Site(s) in Kenya
KEMRICDC, KISUMU, KENYA
 
05-05-2016 View

116.

ECCT/15/11/01   A5264
    A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy   versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of   Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)   
Principal Investigator(s)
1. Dr. Victor Otieno Mudhune
Site(s) in Kenya
1. KEMRI CDC (Kisumu county)
 
05-05-2016 View

117.

ECCT/16/02/05   PfSPZ Malaria Vaccine
    Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy   
Principal Investigator(s)
1. Martina Oneko
2. Mary J Hamel
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Wagai Health Center (Siaya county)
 
18-05-2016 View

118.

ECCT/16/03/02   Infant TB Infection Prevention Study (“iTIPS”)
    Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants       
Principal Investigator(s)
1. Grace John-Stewart
Site(s) in Kenya
1. Kisumu East District Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Bondo sub-County Hospital (Kisumu county)
 
03-06-2016 View

119.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
14-07-2016 View

120.

ECCT/16/06/01   P1115
    Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
KEMRI WALTER REED PROJECT KERICHO
 
25-07-2016 View